Efectividad del concentrado de fibrinógeno en pacientes traumáticos con hemorragia crítica

Celia González Guerrero
USE OF HUMAN PROTHROMBIN COMPLEX CONCENTRATE AND HUMAN FIBRINOGEN CONCENTRATE ADMINISTRATION TO PATIENTS WITH HIGH-RISK OF SEVERE BLEEDING IN A TRAUMA HOSPITAL

González-Guerrero, C., Mestre Galofré, L., Branderiz Nuñez, D., Juárez, J.C., Lalueza, P., Girona, L, Montoro, J.B.
Pharmacy Unit. Hospital Universitari Vall d’Hebron. Barcelona. Spain

Background
Deficiency in prothrombin complex concentrates (PCC) and fibrinogen is a cause of massive haemorrhage whose correct management in emergency situations is controversial.

Methods
Retrospective observational study in a Trauma hospital. Patients with a documented life-threatening haemorrhage who received a PCC or fibrinogen prescription were included in the protocol, during a follow-up period of 6 months. Demographic data, treatment indication, INR (International Normalized Ratio) before and after treatment, admission diagnosis, PCC (II, VII, IX and X factors), fibrinogen dose, current oral anticoagulants (OAT) treatment, as well as data on administration of vitamin K, tranexamic acid or other hemoderivatives (red cells, platelets, plasma) was collected.

Results
A total of 18 patients were included in the study: 9 with PCC, 5 with fibrinogen, and 4 with both drugs. 60% and 71% of patients treated with PCC and fibrinogen, respectively, were women. Patient’s mean age was 52 (range 18-90) for PCC and 58.12 (range 33-81) for fibrinogen.

- 20% of the patients who received PCC were being treated with oral anticoagulants (OAT) prior to the emergency bleeding.
- 64.71% had a politraumatism, and 82.35% were under surgical procedures when the PCC or fibrinogen was administered.

MEAN INR OF ALL PCC PATIENTS:
- PRIOR: 1.73 (SD 0.60).
- AFTER: 1.35 (SD 0.15)
- MEAN DOSE: 1680 UI (600 - 2400 UI). Being the dose referred to the IX factor.

MEAN INR OF OAT PATIENTS WITH PCC (20%):
- PRIOR: 2.60 (SD 0.40)
- AFTER: 1.31 (SD 0.05)
None of the anticoagulated patients were treated with fibrinogen.

FIBRINOGEN:
- PRIOR: fibrinogen mean levels were 1.95 (SD 1.18)
- AFTER: fibrinogen mean levels were 2.53 SD (1.04)
- MEAN DOSE: 2.38g. (1 - 4g.)
- BIOLOGIC RECUPERATION: 131.4 % (45 - 240 %). 1gr of fibrinogen causes an average increase of 0.47 g / L in fibrinogen plasma concentration.

Survival after seven days was:
- For PCC:
  - Anticoagulated: 50% (2patients)
  - Non-anticoagulated:100% (8 patients)
- For fibrinogen: 87.5% (8 patients)

Objective
To ascertain how PCC and fibrinogen are used in patients with life-threatening hemorrhagic disorders (trauma and surgery), especially in patients with underlying disease states that limit PCC synthesis or fibrinogen synthesis.

Conclusions
- PCC treatment normalized INR among anticoagulated patients.
- Fibrinogen administration raised fibrinogen levels to the recommended serum levels range (according to the european guidelines).
- Consensus guidelines are needed for the appropriate therapeutic management of patients with severe bleeding.
- Clinical pharmacist should play an important role when managing patients with severe bleeding.